Anti-TNFR2 monoclonal antibody LBL-019 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose escalation Study.

被引：0
|
作者：
Zhou, Fei
Li, Wei
Chen, Yu
Lin, Jing
Chen, Ling
Zhang, Huishan
Dong, Xiaorong
Tong, Fan
Zhang, Ruiguang
Yin, Yongmei
Liang, Yan
Yang, Nong
Hu, Sheng
Zhuang, Wei
Li, Tao
Cai, Shengli
Zhou, Caicun
机构：
[1] Tongji Univ, Shanghai Pulm Hosp, Dept Med Oncol, Sch Med, Shanghai, Peoples R China
[2] Tongji Univ, Thorac Canc Inst, Sch Med, Shanghai, Peoples R China
[3] Fujian Canc Hosp, Dept Oncol, Fuzhou, Peoples R China
[4] Fujian Canc Hosp, Fuzhou, Peoples R China
[5] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[6] Nanjing Med Univ, Dept Oncol, Affiliated Hosp 1, Nanjing, Peoples R China
[7] Hunan Canc Hosp, Lung Gastrointestinal & Oncol Dept, Changsha, Peoples R China
[8] Hubei Canc Hosp, Dept Internal Med Oncol, Wuhan, Peoples R China
[9] Nanjing Leads Biolabs Co Ltd, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14580
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study
    Moore, Kathleen N.
    Sabanathan, Dhanusha
    Du, Yiqun
    Duan, Huaxin
    Li, Xiumin
    Wang, Feng
    Marathe, Omkar
    Yang, Hua
    Makker, Vicky
    Growdon, Whitfield
    Coward, Jim
    Zhao, Peng
    Liu, Liming
    Shi, Rong
    Liu, Shengxue
    Gu, Wei
    Qiu, Yang
    Zhu, Zhongyuan
    Zhang, Jian
    Hamilton, Erika P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies
    Carneiro, Ana
    Hahn, Amanda
    Ellmark, Peter
    Enell Smith, Karin
    Schultz, Lena
    Ambarkhane, Sumeet
    Yachnin, Jeffrey
    Ullenhag, Gustav J.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (01)
  • [33] A PHASE 1, FIRST IN HUMAN, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY OF TST005 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
    Chen, Lei
    Tolcher, Anthony
    Gabrail, Nashat
    Barve, Minal
    Wu, Xiaohua
    Zhang, Jian
    Shi, Michael
    Qi, Chuan
    Yu, Steven
    Yao, Jenny
    Wang, Jianming
    Cavanaugh, Christopher
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A802 - A802
  • [34] A phase I/II, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors
    Gutierrez, M.
    Garralda, E.
    Calvo, E.
    van Dongen, M.
    Eskens, F. A.
    Finlay, M.
    Menas, F. Z.
    Zhu, C.
    Wu, M.
    Guillemin-Paveau, H.
    Abbadessa, G.
    Perez, R.
    Yildirim, O.
    Naing, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S646 - S647
  • [35] A phase I, multicenter, open-label, first-in-human study to evaluate MEDI0680, an anti-programmed cell death-1 antibody, in patients with advanced malignancies.
    Infante, Jeffrey R.
    Goel, Sanjay
    Tavakkoli, Fatemeh
    Marshall, Shannon
    Robbins, Paul B.
    D'Angelo, Gina
    Gribbin, Matthew Joseph
    Karakunnel, Joyson Joseph
    Naing, Aung
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] A phase I, first-in-human, open-label, dose escalation and expansion study of PT886 in adult patients with advanced gastric, gastroesophageal junction, and pancreatic adenocarcinomas.
    Overman, Michael J.
    Melhem, Ramzi
    Blum-Murphy, Mariela A.
    Ramos, Claudia
    Petrosyan, Lina
    Li, Jack
    Perer, Jessica K.
    Zou, Hui
    Wang, Ming
    Wright, Harold M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS765 - TPS765
  • [37] First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
    Hassan, Raffit
    Blumenschein, George R., Jr.
    Moore, Kathleen N.
    Santin, Alessandro D.
    Kindler, Hedy L.
    Nemunaitis, John J.
    Seward, Shelly M.
    Thomas, Anish
    Kim, Stella K.
    Rajagopalan, Prabhu
    Walter, Annette O.
    Laurent, Dirk
    Childs, Barrett H.
    Sarapa, Nenad
    Elbi, Cem
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (16) : 1824 - +
  • [38] A phase I, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors
    Hua, Y.
    Wang, C.
    Li, F.
    Han, Y.
    Zuo, D.
    Lv, Y.
    Peng, Y.
    Chen, J.
    Yuan, R.
    Zhang, F.
    Wang, Y.
    Wu, H.
    Zhou, G.
    Wang, S.
    Li, N.
    Lu, Y.
    Lin, Q.
    ANNALS OF ONCOLOGY, 2024, 35 : S677 - S677
  • [39] A phase I, first-in-human, randomized dose-escalation study of anti-activated factor XII monoclonal antibody garadacimab
    McKenzie, Andrew
    Roberts, Anthony
    Malandkar, Sourabh
    Feuersenger, Henrike
    Panousis, Con
    Pawaskar, Dipti
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (03): : 626 - 637
  • [40] A phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal antibody, in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors
    Coward, Jermaine
    Ben Markman
    Nagrial, Adnan
    Abed, Afaf
    Walpole, Imogen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345